These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29020511)

  • 1. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.
    Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G
    J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian population finding with biomarkers in a randomized clinical trial.
    Morita S; Müller P
    Biometrics; 2017 Dec; 73(4):1355-1365. PubMed ID: 28257141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup finding via Bayesian additive regression trees.
    Sivaganesan S; Müller P; Huang B
    Stat Med; 2017 Jul; 36(15):2391-2403. PubMed ID: 28276142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees.
    Logan BR; Sparapani R; McCulloch RE; Laud PW
    Stat Methods Med Res; 2019 Apr; 28(4):1079-1093. PubMed ID: 29254443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials.
    Trippa L; Alexander BM
    J Clin Oncol; 2017 Feb; 35(6):681-687. PubMed ID: 28045624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials.
    Xiong W; Roy J; Liu H; Hu L
    Contemp Clin Trials; 2024 Jul; 142():107547. PubMed ID: 38688389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials.
    Lunceford JK
    Pharm Stat; 2015; 14(3):233-341. PubMed ID: 25846276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative interaction trees: a tool to identify qualitative treatment-subgroup interactions.
    Dusseldorp E; Van Mechelen I
    Stat Med; 2014 Jan; 33(2):219-37. PubMed ID: 23922224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian averaging over decision tree models: An application for estimating uncertainty in trauma severity scoring.
    Schetinin V; Jakaite L; Krzanowski W
    Int J Med Inform; 2018 Apr; 112():6-14. PubMed ID: 29500023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
    Berry DA
    Clin Trials; 2005; 2(4):295-300; discussion 301-4, 364-78. PubMed ID: 16281428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree.
    Shen C; Hu Y; Li X; Wang Y; Chen PS; Buxton AE
    Biom J; 2016 Nov; 58(6):1357-1375. PubMed ID: 27356196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSICA: Decision trees for probabilistic subgroup identification with categorical treatments.
    Sysoev O; Bartoszek K; Ekström EC; Ekholm Selling K
    Stat Med; 2019 Sep; 38(22):4436-4452. PubMed ID: 31246349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.